

ANALYST GUIDE First-half FY2015

April 2015



(Listed on the 1st Section of the Tokyo Stock Exchange; Code 7447)

人、いのち、愛。

<Contact for information on this material: Mr. Ohno, Administration Headquarters (03-5289-8200)>

Overview FY2014



1

Achieved the Highest Sales.

- 6th consecutive years of growth in sales
- Sales: $\frac{46,840 \text{ m (y/y } +1.0\%)}{40.0\%}$
- Operating profit: \$1,797 m (y/y -1.9%)

2

The Change of Business Environment

- Market Condition: Stable
- Production Condition: Appreciation of the dollar against the yen.

Escalating material prices, rising sewing costs.

3

Unusual Event in this term

- Exchange-rate profit: First-half FY2013 ¥355m

First-half FY2014 ¥56m

First-half FY2015 ¥220m

- Share purchased in January 2015 1 million shares, 1,500 million yen



Outline

- I Financial Review First-half FY2015
- II Market Environment
- III Forecast for FY2015
- IV Management Goals
- V Rewarding shareholder-focused policies

Outline




Establish competitive position in medical clothing market

- -Approximately 60% market share in domestic medical clothing
- -Wide field, planning, manufacturing and marketing
- -Competitive product such as extensive products, custom-made program

Highly profitability and strong balance sheet

- -Gross profit to sales 46.8% (as of FY2014)
- -Capital-to-asset ratio 88.6%
- -ROE 9.5%




Strong growing market

Strong Stownis interior					
Doctor, Dentist, Pharmacist*1	Nursing Staff*1	Care workers*2			
690,000 people	1,540,000 people	1,490,000 people			
compare with 2010 +13,000people	compare with 2010 +67,000people	compare with 2010 +160,000people			

- **★**1 Annual Report on Health, Labour and Welfere 2012, MHLW
- *2 Survey of care service facilities and business 2012, MHLW

MHLW: Ministry of Health, Labour and Welfare of Japan



I Financial Review First-half FY2015

Financial Highlights <Statements of Income>



(millions of yen,%)	First-half FY2015	% Change	To Forecast %	Composition %	Composition % Change
Net sales	6,840	+1.0	-1.6	100.0	-
Gross profit	3,187	+0.6	-1.5	46.6	-0.2
Sales, general, and administrative expenses	1,390	+3.9	-2.6	20.3	+0.6
Operating income	1,797	-1.9	-0.6	26.3	-0.8
Recurring income	2,033	+5.6	+11.0	29.7	+1.3
Net income	1,302	+3.0	+10.9	19.0	+0.4

[Overview]

- Major business in products for healthcare and peripheral business in products for patients and surgery grew steadily. Sales of high functional products increased specifically. The highest ever sales continued for 6th consecutive years.

[Gross profit] y/y +¥18 m(Factor of increase of Net sales: +¥30m, Factor of increase of profit ratio: -¥12m)

Gross profit to sales FY2014 46.8% \rightarrow FY2015 46.6%

Boost of material cost and sewing cost (-\forall 11m)

Foreign Exchange rate: FY2014 87.4 Yen/dollar → FY2015 91.5 Yen/dollar (-¥35m)

Overseas production ratio FY2014 42.7 % \rightarrow FY2015 45.2 % (+¥43m)

[Sales, general, and administrative expenses]

- Depreciation related with New HQ: ¥35m

[Non-operating income]

- Exchange-rate profit: FY2014 ¥56m FY2015 ¥220m

[Extraordinary profit]

-FY2014 Gain on sale of properties:¥114m

[Capital Expenditure]

- -Capital Expenditure: ¥48m (Software:¥12m, Manufacturing equipment:¥25m)
- -Depreciation: ¥ 176m

Financial Highlights <Balance Sheet>



down ¥1,413million

Major assets			(¥ million %)
Title	Result	Change Result	Change %
Cash on hand at banks	15,510	-506	-3.2
Notes and accounts receivable	4,710	+604	+14.7
Securities	1,517	+1,300	+600.1
Inventories	4,860	+530	+12.3
Current assets	27,177	+2,033	+8.1
Buildings and structures	2,502	-145	-5.5
Land	4,480	0	0.0
Investments and other assets	1,757	-1,193	-40.4
Fixed assets	9,537	-1,413	-12.9
Total assets	36,715	+620	+1.7

Major liabilities and shareholders' equity

(¥ million %)

Title	Result	Change Result	Change%
Notes and accounts payable	1,658	+87	+5.6
Accrued income taxes	694	+83	+13.7
Current liabilities	3,800	+563	+17.4
Capital reserves	33,117	+1,507	+4.8
Treasury stock	▲ 4,902	-1,500	+44.1
Net assets	32,915	+57	+0.2
Total liabilities and net assets	36,715	+620	+1.7

[Major changes from the previous fiscal year]			
Cash and cash equivalents	down ¥506million		
-Cash flows from operating activities	up ¥2,510million		
-Acquisition tangible and intangible	down ¥156million		

fixed assets

Fixed assets

-Share buyback	down ¥1,500million
-Dividend payout	down ¥1,711 million


-Land, Buildings and structures	down ¥145million
-Investments and other assets	down ¥1,246million
(Cashing out financial assets changed to	
the same amount of current assets 'securities'	, less risky bond fund.)

Net assets	up ¥57million
-Net profit	up ¥3,261 million
-Capital reserves	down ¥1,507million
-Share buyback	down ¥1,500million


Segments by item


















Sales by Item





Year-on-year change	First-half FY2014	First-half FY2015
Overall	+4.8%	+1.0%
Healthcare wear	+5.1%	+2.5%
Doctors' wear	+8.4%	-1.7%
Utility wear	-4.9%	-10.9%
Patient wear	+6.3%	+2.9%
Surgery wear	+3.3%	+2.7%
Shoes	-13.0%	-10.6%
Others	+14.0%	-3.5%

Major business in products for healthcare and peripheral business in products for patients and surgery grew steadily.

[Healthcare wear]

-In 2Q, catching renewal contracts which were postponed of 1Q, and focusing on getting new contracts, the highest ever sales continued for 6th consecutive years.

[Doctors' wear]

-As sales of previous year was high, growth of this term was little down. Steady sales condition continued.

[Utility wear]

- Sales fell because institutions changed unit of supply from individual to section and tighten the allocation standard.

[Patient wear]


-As the demand of market expanding, sales increased steadily.

[Surgery wear]

-As penetrating of surgical underwear(scrub) and COMPELPACK into the market, sales increased continuously.

Sales by Region





Year-on-year change	First-half FY2014	First-half FY2015
Total sales	+4.8%	+1.0%
East Japan	0.0%	+0.3%
Central Japan	+25.1%	+1.0%
West Japan	+6.1%	+1.0%
Overseas	+21.6%	+31.5%

In FY2014, sales in Central and West Japan exceeded the previous year and contributed to growth of sales. In FY2015, sales in all area recorded the highest past sales.

[East Japan]

- Catching renewal contracts which were postponed of 1Q, sales kept previous year.

[Central Japan]

-Market size was not large and there was the influence by the size of contracts. In this term, focusing on promotion, sales grew further.

[West Japan]

-Though catching new contracts smoothly, postponement of renewal contracts occured. Sales kept previous year. Sales is expected to increase in secondhalf of FY2015.

[Overseas]

-Due to the impact of depreciation yen, high-growth sales continued.

Market Environment Topics



Care Service treatment fees revised.(effective Apr. 2015)

The revise rate -2.27% (Home-1.42%, Facilities -0.85%) Improvement of care staffs conditions +1.65%, dementia heavy +0.56%, revenue adjustment -4.48%

Forcast of the number of nursing and care staff in 2015

- -Nursing staff 1.65m people Increased by 2.57% annually
- -Care staff 1.76m people Increased by 5.71% annually

Escalating material prices, rising sewing costs

- -The price of polyester increased.
- -The cost of labor charge around China and Southeast Asia raised.

Effect to the cost of overseas production due to appreciation of the dollar against the yen

-monthly average exchange rate in NY market(as of Aug.)

2010:\forall 85/dollar, 2011:\forall 77/dollar, 2012:\forall 77/dollar, 2013:\forall 98/dollar, 2014:\forall 102/dollar

Feb. 2015 ¥120/dollar




Changes and prospects for medical and care service systems

	Medical System		Care Service System		
	Medical Service Law, Health and Medical Service Law for the Aged, Medical Insurance, etc	Medical treatment fees	Care Service Law, Nursing Care Insurance, etc.	Nursing care fees	
'05	Enforcement of Amended Pharmaceutical Affairs Law Release of the 6th prospect for supply and demand of nursing staff				
'06	Proposed draft of reform of medical insurance system submitted. Expansion of DPC to general hospitals.	Total market: -3.16% Service: -1.3% Drug price: -1.8%	Enforcement of Amended Nursing Care Insurance Law 3 rd plan of care insurance system (2006-2008)	Total market: -2.4% Home: -1.0% Facilities: -4.0%	
'07	New Health Frontier Strategy announced Social medical corporations instituted by law		Ban lifted on medical corporations from operating private commercial nursing homes. Nursing care type medical facilities to be abolished in 2012		
'08	Medical program for very elderly instituted by law "Metabolic" diagnosis and health guidance specified as mandatory	Total market: -0.83% Service: +0.38% Drug price: -1.2%	Nursing care type elderly health facilities instituted		
'09	Enforcement of Amended Pharmaceutical Affairs Law Local healthcare revival plan		4 th plan of care insurance system (2009-2011)	Total market: +3.0% Home: +1.7% Facilities: +1.3%	
'10	Release of the 7th prospect for supply and demand of nursing staff. Legal transformation of national medical highly-advanced center into independent administrative corporations	Total market: +0.19% Service: +1.55% Drug price: -1.36%			
'11	Postponed time limit of abolishing nursing care type medical facilities for 6 year. The interim appraisal of the medical expenses		Disapproval of setting up specialty nursing homes for social medical organization.		
'12	Postponed abolishing of Medical Care System for People Aged 75 and over	Total market: +0.004% Service: +1.38% Drug price: -1.38%	Enforcement of Amended Nursing Care Insurance Law 5th plan of care insurance system (2012-2014)	Total market: +1.2% Home: +1.0% Facilities: +0.2%	
' 13	2nd plan of the medical expenses Plan of strategic market creation		Revising of measures against reduction of incidence for nursing care		
' 14	Medical Service Act Enforcement of Amended Pharmaceutical Affairs Law	Total market: +0.10% Service: +0.73% Drug price: -0.63%	The law for Medical care synthesis total promotion	+0.63% Consumption tax increase	
'15	System for promotion of community medical corporation Expansive financial support of national health insurance		System for promotion of community medical corporation 6th plan of care insurance system (2015-2017)	Total market: +2.27% Home: 1.42% Facilities: -0.85%	




Revisions to medical treatment and care Service fees








(Source: the Ministry of Health, Labor and Welfare (December 2010))



- The 7th outlook for nursing staff demand and supply (five-year plan from 2011 through 2015)
- Outlook for nursing staff supply and demand for all medical and nursing fields
- Next outlook for nursing staff supply and demand will be announced in 2015






Since the number of track records are subject to the influence of change of an examination method, it cannot carry out annual comparison simply after 2010.

Actual record :survey of care service facilities and business, Ministry of Health, Labor and Welfare

Forecast: general politics measurement for the aged society, cabinet





Forecast: general politics measurement for the aged society, cabinet

Forecast for FY2015

Management Tasks and Status



Marketing strategy to boost sales

- •Capture clusters of needs in the healthcare wear market
- •Increase peripheral business in products for patients and surgery
- Develop new markets

Production strategy to ensure a steady supply

- •Strengthen ties with material makers and trade firms.
- •Improve Quick Response production system.
- •Develop new production overseas base.

Forecast Statements of Income



(millions of yen,%)	FY2015E	Change (Initial Forecast)	% Change (FY2014)	Composition % Change
Net sales	16,700	_	+3.0	_
Gross profit	7,682	-75	+1.3	-0.8
Sales, general, and administrative expenses	2,751	_	+3.3	+0.1
Operating income	4,931	-75	+0.2	-0.8
Recurring income	5,088	+30	-1.1	-1.3
Net income	3,187	-57	-1.1	-0.8

[Overview]

-Net sales is expected 5th consecutive years of growth and best record. Operating income is expected 6th consecutive years of growth and best record. These will be achieved by putting high functional products in healthcare wear and doctor wear, expanding sales healthy in patient/surgery wear and gaining share in Central and West Japan. Increasing in revenue will overcome growing of cost and expense. Gross profit v/v +¥ 96 m(Factor of increase of Net sales +¥223m, Factor of increase of profit ratio -¥ 127 m)

> Gross profit to sales FY2014 46.8% \rightarrow FY2015E 46.0%

Boost of material cost and sewing cost (-¥58m)

Foreign Exchange rate: FY2014 ¥88.1yen/dollar \rightarrow FY2015E ¥93.3yen/dollar (-¥ 89m)

Overseas production ratio FY2014 43.1% \rightarrow FY2015E 44.4 % (+¥ 53m)

[Sales, general, and administrative expenses]

- Increase of Depreciation related with New HO ¥35m, The cost of 100th anniversaries:¥30m

[Non-operating income]

- FY2014 Exchange-rate profit:\(\frac{4}{87}\)m, Profit on securities sold;\(\frac{4}{67}\)m FY2015 Exchange-rate profit:\(\frac{4}{105}\)m [Extraordinary Profit and loss]
- Gain on sale of properties(old HQ Building):¥114m -FY2014 [Other]
- -Increase of income taxes-deferred, by the effect of tax reform in 2015, lower the corporate tax rate.


[Capital Expenditure]

- -Capital Expenditure: ¥185m (Software:¥65m, Buildings:¥72m, Manufacturing equipment:¥31m)
- -Depreciation: ¥365m

Forecast of Sales by Item



Sales by Item



Year-on-year change	FY2014	FY2015E
Sales	+3.8%	+3.0%
Healthcare wear	+4.4%	+3.8%
Doctors' wear	+4.2%	+2.1%
Utility wear	-6.6%	-8.6%
Patient wear	+6.3%	+6.4%
Surgery wear	+3.2%	+4.2%
Shoes/Others	+1.5%	-3.4%

[Healthcare wear] As renewal demand is stabilized and new products were received well from the market, sales of healthcare wear is expected to increase steadily.

[Utility wear] As the demand being down, the decline in sales of utility wear is expected to continue.


[Patient wear] The increase in sales of patient wear is expected to continue with demand in the health check market.

[Surgery wear] As COMPELPACK and surgical underwear(scrub) being steadily permeated, the increase in sales of surgery wear is expected to continue.

Forecast of Sales by Region



Sales by Region



Year-on-year change	FY2014	FY2015E
Total sales	+3.8%	+3.0%
East Japan	+0.8%	+0.9%
Central Japan	+9.7%	+3.1%
West Japan	+6.0%	+5.3%
Overseas	+24.3%	+25.7%


Each area are expected to increase of sales and continue of the highest ever sales.

[East Japan] Catching renewal orders steadily, the sales in East Japan is expected to increase consistently. [Central and West Japan] As gaining share by sales promotion, the increase of sales is planned, [Overseas] Sales is expected to increase as the impact of depreciation yen.

Product Strategy



Sales by Product




[DC brands] Sales of DC brands is expected to remain same as the previous year. Though existing DC brand products are on the decrease, New brand "Miffy" will contribute to the sale.

[High functional products] As these products being received well from the market, the increase in sales of high functional products is expected to continue by driving the strategy of higher quality and value-added products. [Mass products] As being on downward trend, the shift from mass products, include other company products, to functional products is expected to continue.

Production Strategy



Production(Non-Consolidated)



Composition	FY2014	FY2015E
Domestic production	54.3	53.0
Overseas production	43.1	44.4
Purchased products	2.6	2.6

- -To prepare for escalating of material prices and sewing costs, as developing new production infrastructure in overseas, new factory in Java, Indonesia started to operate in February.
- The shift from Jakarta, where is the existing production place, is planned to finish until the end of 2015.

IV Management Goals

Business Direction



Sales Strategy

- -Increase peripheral business in products for patients and surgery.
- -Gain share In West Japan.
- -Develop and Sale of High Functional products.

Profit Strategy


- -Driving the strategy of higher quality and value-added products.
- -The shift to Overseas production.
- -The minimization of exchange risk

Equalization of the fluctuations in foreign exchange rates by reservation of exchange contracts

Defense against depreciation of yen by dollar deposit


Sales Strategy





Net Sales and Gross Profit to Sales Ratio





Note: Consolidated data since FY1994 are shown. Preceding years represent non-consolidated data.

(¥ million)	
FY201	.7E
Net Sales	17,500
Operating Income	5,300

V Rewarding shareholder-focused policies

Profit Reimbursement to Shareholders



Shareholder-focused policies

- Improvement of transparency by proactive disclosure
- Interactive communication with investors
- Profit reimbursement by high dividends



Dividend policy

- Basic policy is to continue stable dividend payment with payout ratio of 50%


Share buyback

- Acquire expeditiously when our share is undervalued
- Share purchased in January FY2015 1 million shares, 1,500 million yen

The History of Stock Value



	BPS (yen)	EPS (yen)
FY2001	532.5	50.8
FY2002	568.3	48.0
FY2003	604.0	52.4
FY2004	663.0	60.5
FY2005	700.0	56.7
FY2006	732.4	61.0
FY2007	764.3	61.9
FY2008	783.9	57.1
FY2009	791.0	42.9
FY2010	827.0	67.6
FY2011	866.1	72.3
FY2012	902.3	68.9
FY2013	966.2	90.8
FY2014	1,012.7	94.1



^{※1} FY2009: Accrued pension fund withdrawal payment loss ¥1.04b
A dotted line is when there was not outbreak.

Actual Dividends Paid



	Total dividend (Million yen)	Share buyback (Million yen)	Payout ratio (non-c, %)	Total return ratio (non-c, %)
FY2001	475	0	27.6	27.6
FY2002	475	0	29.3	29.3
FY2003	530	1,697	29.7	124.6
FY2004	744	0	36.5	36.5
FY2005	1,117	0	56.9	56.9
FY2006	1,117	0	53.4	53.4
FY2007	1,117	0	53.1	53.1
FY2008	1,083	1,077	56.6	111.2
FY2009	1,040	1,220	57.3	122.2
FY2010	1,127	0	51.4	51.4
FY2011	1,205	226	52.0	61.7
FY2012	1,205	0	55.1	55.1
FY2013	1,541	229	51.3	58.7
FY2014	1,712	0	54.4	E54.4
FY2015E	-	1,500	-	-

Management Philosophy

We will provide medical products and services of the highest quality, as the leading company to link "medical services" and "clothing."

- Consistently challenging spirit to lead the industry
- Achievement of contribution to society
- "Respect for Harmony among People" people are our asset



Notes on this material

This material includes forecasts for the future.

These forecasts are based on the judgment of the Company's management concerning currently available information.

These future projections include assumptions or views based on assumptions, and therefore may be different from the actual outcome, depending upon future circumstances.

The expectations for future results stated by the Company or its management in this material do not represent any warranty that these expectations or particular results will be realized.

The Company is not liable to update any of its forecasts, or projections, unless otherwise provided for by law or under the relevant regulations.

Data File First-half FY2015



(Listed on the 1st Section of the Tokyo Stock Exchange; Code 7447)

<Contact for information on this material: Mr. Ohno, Administration Headquarters (03-5289-8200)>

Index

- 1 ... Sales by Item
- 2 ... Sales by Product
- 3 ... Sales by Region
- 4 ... Rationalization of the Production System and Our Purchasing Strategy (Non-Consolidated)
- 5 ... Statements of Income (Consolidated)
- 6 ... Statements of Income (Non-Consolidated)
- 7 ... Indices (Consolidated)
- 8 ... Indices (Non-Consolidated)
- 9.10 ... Statements of Income (Consolidated Non-Consolidated)
- 11.12 ... Balance Sheet (Consolidated Non-Consolidated)

1. Sales by Item

FY	11/8	12/8	13/8	14/8	15/8E
Sales	14,578	15,175	15,625	16,214	16,700
Healthcare wear	8,675	8,769	9,039	9,440	9,700
Doctors' wear	2,306	2,483	2,566	2,674	2,800
Utility wear	865	864	796	743	700
Patient wear	1,025	1,223	1,273	1,353	1,450
Surgery wear	1,258	1,374	1,479	1,525	1,600
Shoes	271	268	249	237	200
Others	176	191	219	239	250

(¥ million)					
First-half	First-half				
14/8	15/8				
6,775	6,840				
3,914	4,011				
1,064	1,046				
334	298				
617	635				
641	659				
87	77				
114	110				

Change over previous year					
Sales	3.6	4.1	3.0	3.8	3.0
Healthcare wear	4.2	1.1	3.1	4.4	2.8
Doctors' wear	3.6	7.7	3.3	4.2	4.7
Utility wear	-7.5	-0.1	-7.9	-6.6	-5.9
Patient wear	6.6	19.3	4.1	6.3	7.1
Surgery wear	7.4	9.2	7.7	3.2	4.9
Shoes	-5.4	-1.0	-7.0	-5.1	-15.6
Others	6.3	8.3	14.5	9.0	4.5

	(%)
4.8	1.0
5.1	2.5
8.4	-1.7
-4.9	-10.9
6.3	2.9
3.3	2.7
-13.0	-10.6
14.0	-3.5

100.0

57.8

15.7

4.9


9.1

9.5

1.3

1.7

Composition					
Sales	100.0	100.0	100.0	100.0	100.0
Healthcare wear	59.5	57.8	57.9	58.2	58.1
Doctors' wear	15.8	16.4	16.4	16.5	16.8
Utility wear	5.9	5.7	5.1	4.6	4.2
Patient wear	7.0	8.1	8.2	8.3	8.7
Surgery wear	8.6	9.0	9.5	9.4	9.6
Shoes	1.9	1.8	1.6	1.5	1.2
Others	1.2	1.2	1.4	1.5	1.5



(%)

100.0

58.7

15.3

4.4

9.3


9.6


1.1

1.6

2. Sales by Product

•							(¥ million)
FY	11/8	12/8	13/8	14/8	15/8E	First-half 14/8	First-half 15/8
Sales	14,578	15,175	15,625	16,214	16,700	6,775	6,840
DC brand products	998	1,024	933	938	940	394	366
High Functional products	6,216	6,547	7,212	7,795	8,210	3,267	3,457
Standard Functional products	6,232	6,501	6,433	6,462	6,550	2,712	2,617
Mass products	1,130	1,100	1,045	1,017	1,000	400	398
Change over previous year							(%)
Sales	3.6	4.1	3.0	3.8	3.0	4.8	1.0
DC brand products	2.5	2.6	-8.9	0.6	0.1	-2.9	-7.2
High Functional products	10.8	5.3	10.1	8.1	5.3	8.6	5.8
Standard Functional products	-0.4	4.3	-1.0	0.4	1.4	3.4	-3.5
Mass products	-8.0	-2.6	-5.1	-2.7	-1.7	-5.5	-0.6
Composition							(%)
Sales	100.0	100.0	100.0	100.0	100.0	100.0	100.0
DC brand products	6.8	6.8	6.0	5.8	5.6	5.8	5.4
High Functional products	42.6	43.1	46.2	48.1	49.2	48.2	50.5
Standard Functional products	42.7	42.8	41.2	39.9	39.2	40.1	38.3
Mass products	7.8	7.3	6.7	6.3	6.0	5.9	5.8





3. Sales by Region

(¥ million)

FY	11/8	12/8	13/8	14/8	15/8E
Sales	14,578	15,175	15,625	16,214	16,700
East Japan	7,739	8,106	8,390	8,461	8,520
Central Japan	1,550	1,564	1,591	1,745	1,800
West Japan	5,168	5,386	5,508	5,839	6,200
Overseas	119	118	134	167	180

First-half	First-half
14/8	15/8
6,775	6,840
3,422	3,430
779	787
2,503	2,529
70	92

Change over previous year


<u> </u>						
Sales	3.6	4.1	3.0	3.8	3.0	
East Japan	-0.5	4.7	3.5	0.8	0.7	
Central Japan	7.1	0.9	1.7	9.7	3.1	
West Japan	9.2	4.2	2.3	6.0	6.2	
Overseas	1.7	-1.3	13.6	24.3	7.7	L

	(%)
4.8	1.0
0.0	0.3
25.1	1.0
6.1	1.0
21.6	31.5

Composition

oomposition					
Sales	100.0	100.0	100.0	100.0	100.0
East Japan	53.1	53.4	53.7	52.2	51.0
Central Japan	10.6	10.3	10.2	10.8	10.8
West Japan	35.5	35.5	35.3	36.0	37.1
Overseas	0.8	0.8	0.9	1.0	1.1

	(%)
100.0	100.0
50.5	50.2
11.5	11.5
37.0	37.0
1.0	1.3



4. Rationalization of the Production System and Our Purchasing Strategy(Non-Consolidated)

FY	11/8	12/8	13/8	14/8	15/8E
Domestic production	4,921	5,056	4,951	5,061	4,887
Overseas production	3,174	3,441	3,550	4,017	4,095
Purchased products	274	240	224	242	240
Total	8,369	8,737	8,725	9,320	9,222

Change over previous year

Domestic production

	(¥ million)
First-half 14/8	First-half 15/8
2,454	2,495
1,880	2,112
71	66
4,405	4,673

(¥ million) 10,000							(%) 50
7,500						<u></u>	— 45
5,000	~	~					40
2,500							35
0	11/8	12/8	13	3/8	14/8	15/8E	→ 30 E (FY)

Overseas production	17.6	8.4	3.2	13.2	1.9	4.2	12.3
Purchased products	-2.8	-12.6	-6.5	8.0	-0.8	-20.2	-7.0
Total	11.0	4.4	-0.1	6.8	-1.1	0.4	6.1
					_		
Composition							(%)
Domestic production	58.8	57.9	56.7	54.3	53.0	55.7	53.4
Overseas production	37.9	39.4	40.7	43.1	44.4	42.7	45.2
Purchased products	3.3	2.7	2.6	2.6	2.6	1.6	1.4
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0



5. Statements of Income (Consolidated)

385 7,682 3,169 3,762 362 2,751 1,337 1,337 423 4,931 1,831 1,73 42 5,088 1,925 2,03 3,187 1,264 1,33 4.8 3.0 4.8 3.0 4.3 4.5 0.0 4.7 3.3 6.0 3.0 5.0 0.2 3.3 -1.1 1.1 -1.1 -10.7 5.0	f 840 187 890
15/8E 14/8 15/8 214 16,700 6,775 6,8 385 7,682 3,169 3,7 362 2,751 1,337 1,3 42 5,088 1,925 2,6 224 3,187 1,264 1,3 3 1,3 4.5 6 4 3,3 6.0 3 3 0 0.2 3,3 -2 3 -1.1 -10.7 5	340 187 390
214 16,700 6,775 6,8 385 7,682 3,169 3,7 362 2,751 1,337 1,3 423 4,931 1,831 1,7 424 3,187 1,264 1,3 33 1,3 4,5 6,6 3,3 1,3 4,5 6,6 3,3 3,3 6,0 3,3 4,5 6,0 3,3 3,3 4,7 3,3 6,0 3,3 4,8 3,0 3,3 3,3 4,7 3,3 3,3 3,3 4,8 3,3 3,3 3,3 4,9 3,1 3,1 3,1 4,8 3,1 3,1 3,1 4,8 3,1 3,1 3,1 4,9 3,1 3,1 3,1 4,8 3,1 3,1 3,1 4,9 3,1 3,1 3,1 4,8 3,1 3,1 3,1 4,8 3,1 3,1 3,1 4,9 3,1 3,1 3,1 4,8 3,1 3,1 3,1 4,9 3,1 3,1 3,1 4,9	187 390
.662 2,751 1,337 1,337 .23 4,931 1,831 1,733 .42 5,088 1,925 2,633 .24 3,187 1,264 1,333 .3 1,3 4.5 6.0 .7 3,3 6,0 3,33 .0 0,2 3,3 -2,433 .1 -1,1 -10,7 5,5	390
123 4,931 1,831 1,7 42 5,088 1,925 2,0 1,264 1,264 1,3 1	
42 5,088 1,925 2,0 42 3,187 1,264 1,3 .8 3.0 4.8 3.3 .3 1.3 4.5 6.0 .7 3.3 6.0 3.3 .0 0.2 3.3 -2 .1 -1.1 -10.7 5.5	707
.8 3.0 .3 1.3 .7 3.3 .0 0.2 .1 -1.1	7/
.8 3.0 4.8)33
.8 3.0 4.8 .3 1.3 4.5 .7 3.3 6.0 .0 0.2 3.3 .1 -1.1 -10.7	302
.8 3.0 4.8 .3 1.3 4.5 .7 3.3 6.0 .0 0.2 3.3 .1 -1.1 -10.7	
1.3 1.3 4.5 0 1.7 3.3 6.0 3 1.0 0.2 3.3 -1 1.1 -1.1 -10.7 5	%)
.7 3.3 6.0 .0 0.2 3.3 .1 -1.1 -10.7	.0
.0 0.2 3.31 -1.1 -10.7).6
.1 -1.1 -10.7	3.9
	.9
	5.6
.4 -1.1 -4.3	3.0
	%)
0.0 100.0 100.0 10	0.0
6.8 46.0 46.8 4	6.6
6.4 16.5 19.8 2	
0.4 29.5 27.0 2	0.3

FY	11/8	12/8	13/8	14/8	15/8E	First-half 14/8	First-half 15/8
Net Sales	14,578	15,175	15,625	16,214	16,700	6,77!	6,840
Gross profit	6,793	7,103	7,346	7,585	7,682	3,169	9 3,187
Sales, general, and administrative expense	2,434	2,461	2,473	2,662	2,751	1,33	7 1,390
Operating income	4,358	4,642	4,873	4,923	4,931	1,83	1,797
Recurring income	4,277	4,787	5,418	5,142	5,088	1,92	2,033
Net income	2,493	2,371	3,119	3,224	3,187	1,26	1,302
Change over previous year							(%)
Net Sales	3.6	4.1	3.0	3.8	3.0	4.8	
Gross profit	6.3	4.6	3.4	3.3	1.3	4.5	0.6
Sales, general, and administrative expense	2.2	1.1	0.5	7.7	3.3	6.0	3.9
Operating income	8.8	6.5	5.0	1.0	0.2	3.3	-1.9
Recurring income	7.4	11.9	13.2	-5.1	-1.1	-10.7	5.6
Net income	6.4	-4.9	31.5	3.4	-1.1	-4.3	3.0
Composition							(%)
Net Sales	100.0	100.0	100.0	100.0	100.0	100.0	
Gross profit	46.6	46.8	47.0	46.8	46.0	46.8	8 46.6
Sales, general, and administrative expense	16.7	16.2	15.8	16.4	16.5	19.8	8 20.3
Operating income	29.9	30.6	31.2	30.4	29.5	27.0	26.3
Recurring income	29.3	31.5	34.7	31.7	30.5	28.4	4 29.7
Net income	17.1	15.6	20.0	19.9	19.1	18.	7 19.0

6. Statements of Income (Non-Consolidated)

(¥	mil	lion)	١

							(
FY	11/8	12/8	13/8	14/8	15/8E	First-half 14/8	First-half 15/8
Net Sales	14,574	15,166	15,616	16,199	16,700	6,76	6,831
Gross profit	6,464	6,794	7,031	7,270	7,363	3,03	3,053
Sales, general, and administrative expenses	2,413	2,493	2,482	2,662	2,748	1,330	1,383
Operating income	4,051	4,301	4,549	4,608	4,615	1,70	1,669
Recurring income	3,987	4,458	5,177	4,938	4,874	1,90	2,005
Net income	2,322	2,189	3,014	3,145	3,082	1,29	1,318
Change over previous year						(%	(%)
Net Sales	3.6	4.1	3.0	3.7	3.1	4.8	0.9
Gross profit	5.4	5.1	3.5	3.4	1.3	4.6	0.7
Sales, general, and administrative expenses	1.8	3.3	-0.4	7.2	3.2	6.0	4.0
Operating income	7.6	6.2	5.8	1.3	0.1	3.5	-1.9
Recurring income	7.2	11.8	16.1	-4.6	-1.3	-10.7	5.4
Net income	5.9	-5.7	37.7	4.4	-2.0	-4.1	2.2
							
Composition						(%	(%)
Net Sales	100.0	100.0	100.0	100.0	100.0	100.0	100.0
Gross profit	44.4	44.8	45.0	44.9	44.1	44.8	3 44.7
Sales, general, and administrative expenses	16.6	16.4	15.9	16.4	16.5	19.	20.3
Operating income	27.8	28.4	29.1	28.5	27.6	25.	24.4
Recurring income	27.4	29.4	33.2	30.5	29.2	28.	29.4
Net income	15.9	14.4	19.3	19.4	18.5	19.	19.3

7. Indices (Consolidated)

		(Unit)	10/8	11/8	12/8	13/8	14/8	First-ha 14/8
Profitability	ROE	(%)	8.4	8.5	7.8	9.7	9.5	-
	ROA	(%)	12.5	13.0	14.3	15.0	13.5	-
	Return on sales Net income	(%)	16.7	17.1	15.6	20.0	19.9	-
ROE resolution	Total Assets Turnover	(Times)	0.4	0.4	0.4	0.4	0.4	-
	Leverage	(Times)	1.1	1.1	1.1	1.1	1.1	-
	Current Ratio	(%)	743.3	799.9	749.1	768.1	802.1	-
	Fixed Assets Ratio	(%)	27.1	30.4	32.8	32.1	30.1	-
Financial stability	Fixed Assets Ratio to Total of Shareholders' Equity and Long-term Liabilities	(%)	26.6	29.8	32.2	31.5	29.4	-
	Account Receivable Turnover	(Times)	3.3	3.4	3.6	3.5	3.5	-
	Inventory Turnover	(Times)	4.7	5.0	4.7	4.5	4.4	-
	BPS	(¥)	1,653.9	1,732.2	902.3	966.2	1,012.7	95
Per share data	EPS	(¥)	135.2	144.6	68.9	90.8	94.1	3
	DPS	(¥)	-	-	-	-	-	-
	Payout ratio	(%)	48.1	48.4	50.8	49.5	53.1	-
	Free issue/Stock split				2011/9/1 2-for-1			-
Adjusted	Adjusted BPS	(¥)	827.0	866.1	-	-	-	-
Per share data	Adjusted EPS	(¥)	67.6	72.3	-	-	-	-
	Adjusted DPS	(¥)	-	-	-	-	-	-
	Capital expenditure	(¥ million)	209	2,949	285	925	801	
Others	Depreciation	(¥ million)	278	280	270	256	335	
	Number of employees	(Persons)	488	490	501	499	501	
	Personnel expense	(¥ million)	2,147	2,190	2,235	2,245	2,305	1,

First-half	First-half
14/8	15/8
-	-
-	ı
-	ı
-	-
-	-
-	-
-	-
-	-
-	1
-	-
959.5	990.0
36.9	38.1
-	-
-	-
-	-
-	-
-	-
-	-
697	48
147	176
502	497
1,149	1,158

(Note1) Ratio of Fixed Assets to Total of Shareholders' Equity and Long-term Liabilities = Fixed Assets / (Total shareholders' equity + Long-term Liabilities) (Note2) Each of the balance sheet items used in the turnover figures is the average of the balances at the beginning and the end of the financial year.

8. Indices (Non-Consolidated)

		(Unit)	10/8	11/8	12/8	13/8	14/8
Profitability	ROE	(%)	8.4	8.6	7.8	10.3	10.1
	ROA	(%)	12.7	13.1	14.1	15.7	14.2
	Return on sales Net income	(%)	15.6	15.9	14.4	19.3	19.4
ROE resolution	Total AssetsTurnover	(Times)	0.5	0.5	0.5	0.5	0.5
	Leverage	(Times)	1.1	1.1	1.1	1.1	1.1
	Current Ratio	(%)	743.5	716.3	671.0	706.1	735.8
	Fixed Assets Ratio	(%)	28.7	32.4	35.2	34.4	31.9
Financial stability	Fixed Assets Ratio to Total of Shareholders' Equity and Long-term Liabilities	(%)	28.3	31.9	34.8	34.0	31.5
	Account Receivable Turnover	(Times)	3.3	3.4	3.6	3.5	3.5
	Inventory Turnover	(Times)	5.6	6.1	5.8	5.6	5.4
	BPS	(¥)	1,528.7	1,597.0	828.6	883.7	931.9
Per share data	EPS	(¥)	126.5	134.6	63.6	87.8	91.9
	DPS	(¥)	65.0	70.0	35.0	45.0	50.0
	Payout ratio	(%)	51.4	52.0	55.1	51.3	54.4
	Free issue/Stock split				2011/9/1 2-for-1		
Adjusted	Adjusted BPS	(¥)	764.3	798.5	-	-	-
Per share data	Adjusted EPS	(¥)	63.2	67.3	-	-	-
	Adjusted DPS	(¥)	32.5	35.0	-	-	-
	Capital expenditure	(¥ million)	175	2,913	261	846	772
Others	Depreciation	(¥ million)	234	233	233	214	295
	Number of employees	(Persons)	109	108	106	110	112
	Personnel expense	(¥ million)	980	996	999	1,007	1,051

First-half	First-half
14/8	15/8
-	-
-	-
-	-
-	-
-	-
-	1
-	-
-	-
-	-
-	-
877.7	904.9
37.7	38.5
-	-
-	-
-	-
-	-
-	-
-	-
671	38
126	160
111	111
528	555
•	

(Note1) Ratio of Fixed Assets to Total of Shareholders' Equity and Long-term Liabilities = Fixed Assets/ (Total shareholders' equity + Long-term Liabilities) (Note2) Each of the balance sheet items used in the turnover figures is the average of the balances at the beginning and the end of the financial year.

9. Statements of Income (Consolidated)

(¥ million,%)

(¥ million,%)

FY	13	/8	14	1/8	Change(the previous year)		
	Result	Composition	Result	Composition	Result	Change %	
Net Sales	15,625	100.0	16,214	100.0	589	3.8	
Cost of sales	8,278	53.0	8,628	53.2	349	4.2	
Gross profit	7,346	47.0	7,585	46.8	239	3.3	
Sales, general, and administrative expens	2,473	15.8	2,662	16.4	189	7.7	
Packing and freight expenses	222		227				
Advertising expenses	235		263				
Personnel expenses	1,178		1,225				
Management commission expense	128		123				
Depreciation expenses	156		237				
Operating income	4,873	31.2	4,923	30.4	49	1.0	
Non-operating income	621	4.0	261	1.6	-359	-57.9	
Interest income	19		16				
Rent income	59		58				
Others	542		187				
Non-operating expense	76	0.5	42	0.3	-34	-45.0	
Fixed assets rent expense	40		39				
Others	36		2				
Recurring income	5,418	34.7	5,142	31.7	-275	-5.1	
Extraordinary profit	-	0.0	115	0.7	115	-	
Extraordinary loss	344	2.2	26	0.2	-318	-92.3	
Income before income taxes	5,073	32.5	5,231	32.3	158	3.1	
Income, inhabitant and enterprise taxes	2,074		1,902				
Tax adjustments	-120		104				
Net income	3,119	20.0	3,224	19.9	104	3.4	

First-ha	alf 14/8	First-ha	alf 15/8	Change(the previous year)			
Result	Composition	Result	Composition	Result	Change %		
6,775	100.0	6,840	100.0	64	1.0		
3,606	53.2	3,652	53.4	46	1.3		
3,169	46.8	3,187	46.6	18	0.6		
1,337	19.8	1,390	20.3	52	3.9		
101		101					
181		202					
613		644					
60		64					
98		133					
1,831	27.0	1,797	26.3	-33	-1.9		
115	1.7	273	4.0	157	136.4		
8		8					
29		28					
77		236					
21	0.3	38	0.6	16	74.3		
19		18					
2		19					
1,925	28.4	2,033	29.7	107	5.6		
115	1.7	0	0.0	-114	-99.8		
0	0.0	1	0.0	0	94.2		
2,039	30.1	2,031	29.7	-8	-0.4		
622		703					
152		25					
1,264	18.7	1,302	19.0	37	3.0		

10. Statements of Income (Non-Consolidated)

(+	(¥	million,	%)
----------------	----	----------	----

First-half 14/8 First-half 15/8 Change(the previous year) Result Composition Result Composition Result 6,767 100.0 6,831 100.0 64 3,734 55.2 43 3,778 55.3 3,032 44.8 3,053 44.7 20 20.3 1,330 19.7 1,383 197 200 202 181 555 528 61 97 132 1,701 1,669 24.4 -32 25.1 241 3.6 102 63 229 66 57 40 16 0.6 8.0 38 20 1,902 28.1 2,005 29.4 103 1.7 0.0 -114 115 0.0 0.1 29.8 2,003 29.3 -12 2,016 562 647 163 37 1,290 19.1 1,318 19.3 27

(¥ million,%)

Change %

0.9

0.7

-1.9 62.9

40.4

5.4

-99.8

116.3

-0.6

2.2

FY	13	3/8	14	/8	Change(the p	previous year)	
	Result	Composition	Result	Composition	Result	Change %	
Net Sales	15,616	100.0	16,199	100.0	582	3.7	
Cost of sales	8,584	55.0	8,928	55.1	343	4.0	
Gross profit	7,031	45.0	7,270	44.9	238	3.4	
Sales, general, and administrative expenses	2,482	15.9	2,662	16.4	179	7.2	
Packing and freight expenses	433		435				
Advertising expenses	234		262				
Personnel expenses	1,007		1,051				
Management commission expenses	130		126				
Depreciation expenses	153		235				
Operating income	4,549	29.1	4,608	28.5	58	1.3	
Non-operating income	747	4.8	415	2.5	-332	-44.4	
Interest income	17		15				
Dividend income	99		107				
Rent income	128		126				
Others	502		166				
Non-operating expense	119	0.7	86	0.5	-33	-28.3	
Fixed assets rent expense	77		77				
Others	42		8				
Recurring income	5,177	33.2	4,938	30.5	-239	-4.6	
Extraordinary profit	-	0.0	115	0.7	115	-	
Extraordinary loss	343	2.2	26	0.2	-316	-92.3	
Income before income taxes	4,834	31.0	5,027	31.0	192	4.0	
Income, inhabitant and enterprise taxes	1,951		1,763				
Tax adjustments	-131	<u> </u>	117				
Net income	3,014	19.3	3,145	19.4	131	4.4	

11. Balance Sheet (Consolidated)

FY	13/8 14/8			(¥ million,%) Change(the previous year)		First-half 14/8		First-half 15/8		(¥ million, Change(the previous ye		
'' <u> </u>	Result	Composition	Result	Composition	Result	Change %	Result	Composition	Result	Composition	Result	Change %
Current assets	26,247	70.8	29,589	75.6	3,342	12.7	25,144	69.7	27,177	74.0	2,033	8.
Cash on hand and at banks	17,456	70.6	19,054	75.0	3,342	12.7	16,016		15,510		2,033	0.
Trade notes and accounts receivable	4,622		4,696				4,106		4,710			
	216		,				216		1,517			
Securities			1,516									
Inventories	3,524		3,835				4,330		4,860			
Others	428		488				474		579			
Reserve bad debt	0	22.2	-1	24.4			0		-1	21.2		
Fixed assets	10,807	29.2	9,560	24.4	-1,246	-11.5	10,951	30.3	9,537	26.0	-1,413	-12.9
Tangible fixed assets	7,639	20.6	7,837	20.0	197	2.6	7,914	21.9	7,709	21.0	-205	-2.6
Buildings and structures	1,645		2,570				2,647		2,502			
Machinery and equipment	476		594				577		543			
Land	4,692		4,480				4,480		4,480			
Construction in progress	768		-				-		6			
Others	57		192				208		176			
Intangible fixed asset	88	0.3	71	0.2	-16	-18.5	85	0.2	70	0.2	-14	-17.1
Investments and other assets	3,079	8.3	1,651	4.2	-1,428	-46.4	2,951	8.2	1,757	4.8	-1,193	-40.4
Investment securities	1,753		537				1,820		573			
Others	1,327		1,116				1,132		1,187			
Reserve bad debt	-1		-3				-1		-3			
Total assets	37,054	100.0	39,150	100.0	2.095	5.7	36,095	100.0	36,715	100.0	620	1.7
							-					
Current liabilities	3,356	9.1	3,605	9.2	248	7.4	2,585	7.2	2,875	7.9	289	11.2
Trade notes and accounts payable	1,385		1,517									
Accrued income taxes						_	1,570		1,658			
	1,344		1,317				1,570 610		694			
Accrued bonus	82		1,333 81				610 77		694 76			
			1,333				610		694			
Accrued bonus	82	1.6	1,333 81	2.2	253	41.5	610 77		694 76		273	42.0
Accrued bonus Others	82 544	1.6	1,333 81 671	2.2	253	41.5	610 77 327	1.8	694 76 446		273	42.0
Accrued bonus Others Long-term liabilities	82 544 610	1.6	1,333 81 671 863	2.2	253	41.5	610 77 327 650	1.8	694 76 446 924	2.5	273	42.0
Accrued bonus Others Long-term liabilities Accrued pension and severance costs	82 544 610 343	1.6	1,333 81 671 863 580 180	2.2	253	41.5	610 77 327 650 376	1.8	694 76 446 924 631 189	2.5	273	42.0
Accrued bonus Others Long-term liabilities Accrued pension and severance costs Directors' retirement allowances Others	82 544 610 343 168	1.6	1,333 81 671 863 580		253		610 77 327 650 376 174	1.8	694 76 446 924 631	2.5		42.0 17.4
Accrued bonus Others Long-term liabilities Accrued pension and severance costs Directors' retirement allowances Others Total liabilities	82 544 610 343 168 98 3,966	10.7	1,333 81 671 863 580 180 101 4,468	11.4	502	12.7	610 77 327 650 376 174 99 3,236	1.8	694 76 446 924 631 189 102 3,800	2.5		
Accrued bonus Others Long-term liabilities Accrued pension and severance costs Directors' retirement allowances Others Total liabilities Total shareholders' equity	82 544 610 343 168 98 3,966 32,768		1,333 81 671 863 580 180 101 4,468 34,450				610 77 327 650 376 174 99 3,236	9.0 90.0	694 76 446 924 631 189 102 3,800 32,498	2.5		17.4
Accrued bonus Others Long-term liabilities Accrued pension and severance costs Directors' retirement allowances Others Total liabilities Total shareholders' equity Capital stock	82 544 610 343 168 98 3,966 32,768 1,925	10.7	1,333 81 671 863 580 180 101 4,468 34,450	11.4	502	12.7	610 77 327 650 376 174 99 3,236 32,491	9.0 90.0	694 76 446 924 631 189 102 3,800 32,498 1,925	2.5 10.4 88.5		17.4
Accrued bonus Others Long-term liabilities Accrued pension and severance costs Directors' retirement allowances Others Total liabilities Total shareholders' equity Capital stock Capital reserves	82 544 610 343 168 98 3,966 32,768 1,925 2,358	10.7	1,333 81 671 863 580 180 101 4,468 34,450 1,925 2,358	11.4	502	12.7	610 77 327 650 376 174 99 3,236 32,491 1,925 2,358	9.0 90.0	694 76 446 924 631 189 102 3,800 32,498 1,925 2,358	2.5 10.4 88.5		17.4
Accrued bonus Others Long-term liabilities Accrued pension and severance costs Directors' retirement allowances Others Total liabilities Total shareholders' equity Capital stock Capital reserves Retained earnings	82 544 610 343 168 98 3.966 32,768 1,925 2,358 31,886	10.7	1,333 81 671 863 580 180 101 4,468 34,450 1,925 2,358 33,569	11.4	502	12.7	610 77 327 650 376 174 99 32,36 32,491 1,925 2,358 31,609	9.0 90.0	694 76 446 924 631 189 102 3,800 32,498 1,925 2,358 33,117	2.5 10.4 88.5		17.4
Accrued bonus Others Long-term liabilities Accrued pension and severance costs Directors' retirement allowances Others Total liabilities Total shareholders' equity Capital stock Capital reserves Retained earnings Treasury stock	82 544 610 343 168 98 3,966 32,768 1,925 2,358	10.7	1,333 81 671 863 580 180 101 4,468 34,450 1,925 2,358	11.4	502	12.7 5.1	610 77 327 650 376 174 99 3,236 32,491 1,925 2,358	9.0 90.0	694 76 446 924 631 189 102 3,800 32,498 1,925 2,358	2.5 10.4 88.5		17.4
Accrued bonus Others Long-term liabilities Accrued pension and severance costs Directors' retirement allowances Others Total liabilities Total shareholders' equity Capital stock Capital reserves Retained earnings Treasury stock Valuation and translation adjustments	82 544 610 343 168 98 3,966 32,768 1,925 2,358 31,886 -3,401 320	10.7 88.4	1,333 81 671 863 580 180 101 4,468 34,450 1,925 2,358 33,569 -3,402 231	11.4 88.0	502 1,682	12.7	610 77 327 650 376 174 99 3,236 32,491 1,925 2,358 31,609 -3,401 367	9.0 90.0	694 76 446 924 631 189 102 3,800 32,498 1,925 2,358 33,117 -4,902	2.5 10.4 88.5	56 <u>3</u> 7	17.4 0.0
Accrued bonus Others Long-term liabilities Accrued pension and severance costs Directors' retirement allowances Others Total liabilities Total shareholders' equity Capital stock Capital reserves Retained earnings Treasury stock Valuation and translation adjustments Net unrealized gains on investment securitie	82 544 610 343 168 98 3,966 32,768 1,925 2,358 31,886 -3,401 320 78	10.7 88.4	1,333 81 671 863 580 180 101 4,468 34,450 1,925 2,358 33,569 -3,402 231 137	11.4 88.0	502 1,682	12.7 5.1	610 77 327 650 376 174 99 3,236 32,491 1,925 2,358 31,609 -3,401 367	9.0 90.0	694 76 446 924 631 189 102 3,800 32,498 1,925 2,358 33,117 -4,902 416	2.5 10.4 88.5	56 <u>3</u> 7	17.4 0.0
Accrued bonus Others Long-term liabilities Accrued pension and severance costs Directors' retirement allowances Others Total liabilities Total shareholders' equity Capital stock Capital reserves Retained earnings Treasury stock Valuation and translation adjustments Net unrealized gains on investment securitie Deferred hedging gains and losses	82 544 610 343 168 98 3,966 32,768 1,925 2,358 31,886 -3,401 320	10.7 88.4	1,333 81 671 863 580 180 101 4,468 34,450 1,925 2,358 33,569 -3,402 231	11.4 88.0	502 1,682	12.7 5.1	610 77 327 650 376 174 99 3,236 32,491 1,925 2,358 31,609 -3,401 367	9.0 90.0	694 76 446 924 631 189 102 3,800 32,498 1,925 2,358 33,117 -4,902 416 160 363	2.5 10.4 88.5	56 <u>3</u> 7	17.4 0.0
Accrued bonus Others Long-term liabilities Accrued pension and severance costs Directors' retirement allowances Others Total liabilities Total shareholders' equity Capital stock Capital reserves Retained earnings Treasury stock Valuation and translation adjustments Net unrealized gains on investment securitie	82 544 610 343 168 98 3,966 32,768 1,925 2,358 31,886 -3,401 320 78	10.7 88.4	1,333 81 671 863 580 180 101 4,468 34,450 1,925 2,358 33,569 -3,402 231 137 208	11.4 88.0	502 1,682	12.7 5.1	610 77 327 650 376 174 99 3,236 32,491 1,925 2,358 31,609 -3,401 367	9.0 90.0	694 76 446 924 631 189 102 3,800 32,498 1,925 2,358 33,117 -4,902 416	2.5 10.4 88.5	56 <u>3</u> 7	17.4 0.0

12. Balance Sheet (Non-Consolidated)

					(¥	million,%)						¥ million,%)
FY	13/8		14/8 Change(the previous year)				First-ha	alf 14/8	First-half 15/8 Change(the previous year)
	Result	Composition	Result	Composition	Result	Change %	Result	Composition	Result	Composition	Result	Change %
Current assets	23,325	68.8	26,568	74.1	3,242	13.9	22,212	67.5	24,115	72.4	1,902	8.6
Cash on hand and at banks	15,347		16,888				14,085		13,550			
Trade notes	3,051		2,984				1,836		1,928			
Accounts receivable	1,570		1,710				2,268		2,781			
Securities	216		1,516				216		1,517			
Inventories	2,812		3,122				3,449		3,978			
Others	327		347				356		360			
Reserve bad debt	0		-1				0		-1			
Fixed assets	10,559	31.2	9,286	25.9	-1,273	-12.1	10,703	32.5	9,184	27.6	-1,519	-14.2
Tangible fixed assets	7,532	22.2	7,740	21.6	207	2.8	7,800	23.7	7,618			
Buildings and structures	1,603	22.2	2,522	21.0	207	2.0	2,596		2,452		102	2.0
Machinery and equipment	362		483				455		439			
Land	4,692		4,480				4,480		4,480			
Construction in progress	768		4,400				4,400		4,400			
Others	105		253				268		240			
Intangible fixed asset	82	0.3	67	0.2	-15	-18.5	80	0.2	66		-13	-16.9
Investments and other assets	2,945	8.7	1,479	4.1	-1,466	-49.8	2,822	8.6	1,499			
	1,753	0.7	537	4.1	-1,400	-49.0	1,820	0.0	573		-1,323	-40.9
Investment securities Others	1,753		944				1,820		928			
	1,193						1		928			
Reserve bad debt	- l	100.0	-3 35.855	100.0	1.969	F 0	32,916	100.0	-3 33,299	100.0	000	1.0
Total assets	33.885	100.0	35,855	100.0	1,969	5.8	32,916	100.01	33,299	100.0	383	3 1.2
Current liabilities	3,245	9.6	3,535	9.9	290	9.0	2,468	7.5	2,809	8.4	341	13.8
Trade notes	822	7.0	899	7.7	270	7.0	919	7.0	1,014		0.1	10.0
Accounts payable	717		843				755		864			
Accrued income taxes	1,273		1,251				550		637			
Others	432		541				243		293			
Long-term liabilities	377	1.1	404	1.1	27	7.2	390	1.2	403		13	3.4
Accrued pension and severance costs	134	1.1	148	1.1	21	1.2	141	1.2	139		1	3.4
Directors' retirement allowances	144		154				141		161			
Others	98		101				99		101			
Total liabilities	3,622		3.940	11.0	317	0.0	2.859		3.213		354	12.4
Total shareholders' equity				88.5	1,604	8.8 5.3	29,870		29,835			
Capital stock	30,120 1,925	88.9	31,725 1,925	88.5	1,604	5.3	1,925	90.7	29,835 1,925		-32	-0.1
	2,637		2,637				2,637		2,637			
Capital reserves Retained earnings							28,709		2,637 30,174			
	28,959 -3,401		30,564 -3,402				-3,401		-4,902			
Treasury stock Valuation and translation adjustments	-3,401 142	0.4	-3,402 190	0.5	47	33.0	186	0.6	-4,902 251	0.8	64	34.5
Net unrealized gains on investment securitie	142 78		190	0.5	47	33.0	121	0.6	<u>251</u>		02	34.5
Deferred hedging gains and losses	78 64		52				65		90			
Total net assets	30,263	89.3	31,915	89.0	1,651	5.5	30.056	91.3	30,086		29	9 0.1
Total liabilities and total net assets	33,885	100.0	35,855	100.0	1,969	5.8	32,916	100.0	33,299	100.0	383	1.2